Tumor lysis syndrome cost-effectiveness of therapy
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2]
Overview
Overview
In patients with malignancies, the cost-effectiveness of administration of a singe low dose (3 mg) of rasburicase for tumor lysis syndrome prevention may be superior to the daily intravenous allopurinol.
Cost-Effectiveness of Therapy
Cost-Effectiveness of Therapy
In patients with malignancies, the cost-effectiveness of administration of a singe low dose (3 mg) of rasburicase for tumor lysis syndrome prevention may be superior to the daily intravenous allopurinol.[1]
References
References
- ↑ Patel S, Le A, Gascon S (2012). “Cost-effectiveness of rasburicase over i.v. allopurinol for treatment of tumor lysis syndrome”. Am J Health Syst Pharm. 69 (12): 1015–6. doi:10.2146/ajhp110656. PMID 22644973.
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH